ATE215949T1 - Hydroisochinolinderivate - Google Patents

Hydroisochinolinderivate

Info

Publication number
ATE215949T1
ATE215949T1 AT94924764T AT94924764T ATE215949T1 AT E215949 T1 ATE215949 T1 AT E215949T1 AT 94924764 T AT94924764 T AT 94924764T AT 94924764 T AT94924764 T AT 94924764T AT E215949 T1 ATE215949 T1 AT E215949T1
Authority
AT
Austria
Prior art keywords
pct
derivatives
sec
nitrogen
zero
Prior art date
Application number
AT94924764T
Other languages
English (en)
Inventor
Giulio Dondio
Silvano Ronzoni
Original Assignee
Smithkline Beecham Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT93MI001788A external-priority patent/IT1265043B1/it
Priority claimed from ITMI940202A external-priority patent/IT1274008B/it
Application filed by Smithkline Beecham Spa filed Critical Smithkline Beecham Spa
Application granted granted Critical
Publication of ATE215949T1 publication Critical patent/ATE215949T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Lubricants (AREA)
  • Catalysts (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT94924764T 1993-08-06 1994-07-14 Hydroisochinolinderivate ATE215949T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT93MI001788A IT1265043B1 (it) 1993-08-06 1993-08-06 Derivati di idroisochinolina
ITMI940202A IT1274008B (it) 1994-02-04 1994-02-04 Derivati di idroisochinolina
PCT/EP1994/002325 WO1995004734A1 (en) 1993-08-06 1994-07-14 Hydroisoquinoline derivatives

Publications (1)

Publication Number Publication Date
ATE215949T1 true ATE215949T1 (de) 2002-04-15

Family

ID=26331034

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94924764T ATE215949T1 (de) 1993-08-06 1994-07-14 Hydroisochinolinderivate

Country Status (11)

Country Link
US (1) US5731322A (de)
EP (1) EP0712402B1 (de)
JP (1) JPH09505030A (de)
CN (1) CN1043641C (de)
AT (1) ATE215949T1 (de)
AU (1) AU690576B2 (de)
CA (1) CA2168853A1 (de)
DE (1) DE69430373T2 (de)
ES (1) ES2173921T3 (de)
NZ (1) NZ271338A (de)
WO (1) WO1995004734A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450073C (en) 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
JP4417108B2 (ja) 2001-10-15 2010-02-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 新規な置換された4−フェニル−4−[1h−イミダゾール−2−イル]−ピペリジン誘導体および選択的非ペプチドデルタオピオイドアゴニストとしてのそれらの使用
KR20140015122A (ko) 2003-10-01 2014-02-06 아돌로 코포레이션 스피로시클릭 헤테로시클릭 유도체 및 이의 사용 방법
US7087749B2 (en) * 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
US7598261B2 (en) 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
EP2671508B1 (de) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-Informatiksystem
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
WO2008033299A2 (en) 2006-09-12 2008-03-20 Adolor Corporation Use of n-containing spirocompounds for the enhancement of cognitive function
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質(rap)結合体の投与による肝障害の処置
US7645801B2 (en) * 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
KR20180114970A (ko) 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US20100311782A1 (en) * 2009-06-08 2010-12-09 Adolor Corporation Substituted piperidinylpropanoic acid compounds and methods of their use
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2012094618A1 (en) 2011-01-07 2012-07-12 Corcept Therapeutics, Inc. Combination steroid and glucocorticoid receptor antagonist therapy
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
ES2943542T3 (es) 2013-11-25 2023-06-14 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
AU2018244928B2 (en) 2017-03-31 2023-10-19 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CN113194931B (zh) 2018-12-19 2023-11-10 科塞普特治疗公司 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
NZ778399A (en) 2019-02-22 2024-11-29 Corcept Therapeutics Inc Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
CN110330465B (zh) * 2019-06-28 2021-05-11 深圳市三启药物开发有限公司 腙酰胺类衍生物及其在制备防治脱发药物中的应用
JP7569492B2 (ja) 2019-12-11 2024-10-18 コーセプト セラピューティクス, インコーポレイテッド 抗精神病薬誘発性体重増加のミリコリラントによる治療方法
EP4157276A4 (de) 2020-05-27 2024-06-12 Corcept Therapeutics Incorporated Gleichzeitige verabreichung von glucocorticoidrezeptormodulator-relactorilanz und paclitaxel, einem doppelsubstrat von cyp2c8 und cyp3a4
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12616698B2 (en) 2021-05-05 2026-05-05 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders
WO2024077169A1 (en) 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators
US12433882B2 (en) 2022-10-28 2025-10-07 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260762A (en) * 1979-09-10 1981-04-07 Hoffmann-La Roche Inc. Octahydro-1H-pyrrolo[2,3-g]isoquinolines
ES2173866T3 (es) * 1991-07-05 2002-11-01 Glaxosmithkline Spa Derivados de hidroisoquinolina.

Also Published As

Publication number Publication date
DE69430373D1 (de) 2002-05-16
AU690576B2 (en) 1998-04-30
ES2173921T3 (es) 2002-11-01
JPH09505030A (ja) 1997-05-20
CN1043641C (zh) 1999-06-16
AU7493794A (en) 1995-02-28
US5731322A (en) 1998-03-24
EP0712402A1 (de) 1996-05-22
CN1132510A (zh) 1996-10-02
NZ271338A (en) 1998-06-26
DE69430373T2 (de) 2002-12-12
WO1995004734A1 (en) 1995-02-16
EP0712402B1 (de) 2002-04-10
CA2168853A1 (en) 1995-02-16

Similar Documents

Publication Publication Date Title
DE69430373D1 (de) Hydroisochinolinderivate
TW367327B (en) Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation and their use
DE69618231D1 (de) TETRAHYDROIMIDAZOPYRIDOINDOLDIONE ALS cGMP SPEZIFISCHE PDE HEMMER
IL123701A0 (en) Heterocyclic fungicides
NZ331001A (en) Use of an opiate K receptor agonist as an antipruritic
MY102842A (en) Calcium independent camp phosphodiesterase inhibitor antidepressant
NO20003133D0 (no) Anilidderivater, fremstilling og anvendelse derav
AU2003301020A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
YU231790A (sh) Spirocikli koji sadrže azot
GR3036657T3 (en) Method of preventing nmda receptor-mediated neuronal damage.
IL141410A0 (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
KR950701911A (ko) 피페리딘 유도체를 유효성분으로 하는 말초혈관확장제(peripheral vaso-dilating agent containing piperidine derivative as active ingredient)
NZ233735A (en) Heterocyclic substituted aminophenol derivatives
ATE302606T1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
MY108885A (en) Heterocyclic-cyclic amine derivatives.
ATE175661T1 (de) Benzamid-derivate als vasopressin-antagonisten
MY117092A (en) Chemotherapeutic pyrrolocarbazole derivatives
DE69733843D1 (de) Zusammensetzungen und verwendungvon benzamiden als entzuendungshemmende mittel
DK0960111T3 (da) Morphinderivat med analgesisk aktivitet
DE59510713D1 (de) N-substituierte 3-azabicyclo(3.2.0)heptan-derivate als neuroleptika
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
DE3671890D1 (de) Benzylaminoxidaseinhibitoren, selektiv in beziehung auf andere aminoxidasen.
MX9709466A (es) Medicamento para inhibir el melanoma.
ATE47135T1 (de) Antikonvulsive mittel.
DE69526097D1 (de) Bicyclische carboxamide als 5-ht1a rezeptoren liganden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties